Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Immunotherapy × tremelimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 22 Carcinoma, Non-Small-Cell Lung 10 Colorectal Neoplasms 8 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Mesothelioma, Malignant 5 Melanoma 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Stomach Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Mesothelioma 2 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vascular Neoplasms 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04169841 2024-02-13

GUIDE2REPAIR

Centre Georges Francois Leclerc

Phase 2 Active not recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡